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Abstract 
The main objective of this work was to synthesize novel compounds with a benzo[de][1,2,4]triazolo[5,1‑a]isoquinoline 
scaffold by employing (dioxo‑benzo[de]isoquinolin‑2‑yl) thiourea as a building block. Molecular docking was con‑
ducted in the COX‑2 active site to predict the plausible binding mode and rationalize the structure–activity relation‑
ship of the synthesized compounds. The structures of the synthesized compounds were confirmed by HREI‑MS, and 
NMR spectra along with X‑ray diffraction were collected for products 1 and 5. Thereafter, anti‑inflammatory effect of 
molecules 1–20 was evaluated in vivo using carrageenan‑induced paw edema method, revealing significant inhibi‑
tion potency in albino rats with an activity comparable to that of the standard drugs indomethacin. Compounds 8, 
9, 15 and 16 showed the highest anti‑inflammatory activity. However, thermal sensitivity‑hot plat test, a radiological 
examination and motor coordination assessment were performed to test the activity against rheumatoid arthritis. 
The obtained results indicate promising anti‑arthritic activity for compounds 9 and 15 as significant reduction of the 
serum level of interleukin‑1β [IL‑1β], cyclooxygenase‑2 [COX‑2] and prostaglandin E2 [PGE2] was observed in CFA rats.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Inflammation is an important defense mechanism against 
infective, chemical, and physical aggressions. Deregula-
tion of this mechanism can lead to pathological perturba-
tions in the body, as observed for example with allergies, 
autoimmune diseases and organ transplantation rejec-
tion [1]. A key modulator of the inflammatory response is 
prostaglandin  E2  (PGE2), generated at the inflammation 
site from arachidonic acid via the cyclooxygenase (COX) 
enzyme [2].
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
widely used against inflammation, as for example in the 
treatment of chronic and acute inflammation [3], pain 
management [4], and fever [5]. However, cardiovascu-
lar problems, gastrointestinal lesions and nephrotoxicity 
have been observed in case of long NSAIDs treatment 
[6]. Therefore, the discovery of novel anti-inflammatory 
drugs with less side effects remains an intensive area of 
research in medicinal chemistry. Two isoforms of the 
cyclooxygenase have been characterized: COX-1 and 
COX-2. COX-2 levels increase after inflammatory stimuli 
induced by mitogens or cytokines, and can be lowered 
by glucocorticoids [7]. Recent discovery indicates that 
renal toxicity and gastrointestinal side effects observed 
with NSAIDs can be due to COX-1 inhibition, while 
selective inhibition of COX-2 shows a comparable anti-
inflammatory response with less side effects [8]. As an 
example, naproxen is a non-selective COX inhibitor, like 
oxicam, it belongs to a group of NSAID displaying mixed 
COX inhibition, characterized by slow, reversible, and 
weak inhibitor binding. Contrary to other NSAIDs that 
inhibit COX reversibly and rapidly (mefenamic acid and 
ibuprofen), or irreversibly and slowly (indomethacin and 
diclofenac), naproxen contributes to the cardioprotective 
effect because of their weak inhibition of COX [9].
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The quinolone ring system is often found in synthetic 
compounds with various biological activities, including 
anti-convulsant [10], anti-malarial [11], anti-microbial 
[12], and anti-inflammatory [13] effects. Quinolines and 
their isomers isoquinolines are also found in various 
natural products, such as quinine (anti-malarial) and qui-
nidine (anti-arrhythmic) [14]. Furthermore, many isoqui-
noline alkaloids, including cepharanthine, berberine and 
tetrandine, have shown anti-inflammatory effect [15]. 
The binding affinity and the solubility in physiological 
conditions can be considerably affected by the position 
of the nitrogen bearing a side chain on the isoquinoline 
skeleton [16]. Therefore, a huge effort has been spent in 
developing novel and effective isoquinoline derivatives. 
On the other hand, the triazole moiety is found in many 
important biologically active compounds. Synthesized 
molecules with a triazole moiety possess anti-tubercular 
[17], antimicrobial [18], anti-cancer [19] and anti-inflam-
matory [20] activity. Triazole-based heterocyclic deriva-
tives have enhanced biological activity or possess new 
biological activities [21]. A wide range of triazole con-
taining compounds are clinically used drugs and devel-
oped via molecular hybridization approach including 
anticancer, antifungal, antibacterial, antiviral, antituber-
cular, anti-inflammatory, antiparasitic, anticonvulsant, 
antihistaminic and other biological activities [21]. There-
fore, triazole and isoquinoline can be promising chemi-
cal fragments for the design of novel anti-inflammatory 
drugs.
Considering the importance of the isoquinoline and 
triazole moieties in the wide range of anti-inflammatory 
treatments and its interesting activity profile, we con-
ducted a molecular-hybridization design of novel anti-
inflammatory compounds. Toward the development of 
new effective and selective anti-inflammatory agents, the 
[1,2,4]triazole and [5,1-a]isoquinoline were integrated to 
develop a novel class of inhibitor.
Materials and methods
Melting points were determined on open glass capillar-
ies using a STUART Melting point SMP 10 apparatus and 
are uncorrected. NMR spectra were recorded on a Bruker 
AMX 500 spectrometer in DMSO-d6 and reported as δ 
ppm values relative to TMS at 500/700 and 125/176 MHz 
for 1H and 13C NMR, respectively. J values were recorded 
in Hz. HREI-MS spectra were measured on a JEOL 
MStation JMS-700 system. X-ray data were collected 
on a Bruker APEX-II D8 Venture area diffractometer, 
equipped with graphite monochromatic Mo Kα radia-
tion, λ = 0.71073 Å at 100 (2) K. Follow-up of the reac-
tions and checking the purity of compounds was made by 
TLC on DC-Mikrokarten polygram SIL G/UV254, from 
the Macherey–Nagel Firm, Duren Thickness: 0.25 mm.
Procedure for preparation of 1‑(1,3‑dioxo‑1H‑benzo[de]
isoquinolin‑2(3H)‑yl)thiourea (1)
To a solution of 1,8-naphthalic anhydride (2.2 mmol) in 
boiling glacial acetic acid (15  mL), thiosemicarbazide 
(2.8  mmol) was added and left the mixture stirring 
under reflux for 1  h. The obtained solid was separated 
and washed with water. Recrystallization by a mixture 
of toluene and DMF yielded the final product as color-
less crystals (90%); mp 243–244 °C; 1H NMR (500 MHz, 
DMSO-d6): δ 9.82 (s, 1H, –NH–), 8.55 (br d, J =  8 Hz, 
2H, H-3/8), 8.51 (br d, J  =  8  Hz, 2H, H-5/6), 7.99 (br 
s, 2H, –NH2), 7.92 (t, J  =  8  Hz, 2H, H-4/7); 13C NMR 
(125  MHz, DMSO-d6): δ 181.8 (C=S), 162.0 (C-2/9), 
134.7 (C-5/6), 131.3 (C-5a), 130.9 (C-3/8), 127.3 (C-4/7), 
122.7 (C-2a/8a), 119.0 (C-2b); HRMS (EI), m/z Calcd for 
 C13H9N3O2S (M)•+ 271.0983, found 271.1013.
Procedure for preparation of 10‑(methylthio)‑7H‑benzo[de]
[1,2,4]triazolo[5,1‑a]isoquinolin‑7‑one (3)
A mixture of I or 2 (1 mmol) with dimethyl-N-cyanoimi-
dodithiocarbonate (1 mmol) in N,N-dimethyl formamide 
(10  mL) was refluxed in the presence of triethylamine 
for 4  h. Afterwards, the mixture was poured into ice/
water, the resulting solid was filtered, washed with water 
and dried. Analytically pure product obtained as yellow 
amorphous powder (67%); mp 268–269  °C; 1H NMR 
(700 MHz, DMSO-d6): δ 8.75 (br d, J = 7.7 Hz, 1H, H-6), 
8.61 (br d, J = 8.4 Hz, 1H, H-3), 8.59 (br d, J = 8.4 Hz, 1H, 
H-8), 8.47 (br d, J = 7.7 Hz, 1H, H-5), 7.99 (t, J = 7.7 Hz, 
1H, H-4), 7.93 (t, J = 7.7 Hz, 1H, H-7), 2.73 (s, 3H, –S–
CH3); 13C NMR (176  MHz, DMSO-d6): δ 166.0 (C-9), 
156.6 (>C–S–CH3), 155.9 (C-2), 137.0 (C-6), 134.3 (C-3), 
133.5 (C-5), 132.3 (C-8a), 128.4 (C-8), 128.1 (C-4), 128.0 
(C-7), 126.1 (C-5a), 122.9 (C-2b), 118.2 (C-2a), 14.2 (S-
CH3); EI-MS, m/z (%): 267 [(M·+, 100)]; HRMS (EI), m/z 
Calcd for  C14H9N3OS (M)·+ 267.0466, found 267.0490.
Procedure for preparation of 10‑(methylsulfonyl)‑7H‑benz
o[de][1,2,4]triazolo[5,1‑a]isoquinolin‑7‑one (5)
An amount of 3 (1  mmol) was dissolved in boiling gla-
cial acetic acid (12  mL), afterward  H2O2 (12  mL), was 
added dropwise over a period of 10  min., while heat-
ing. After the addition was complete, the mixture was 
poured into hot water and left at room temperature, the 
obtained solid was collected, washed with water and 
dried. Recrystallization from DMF gave analytically pure 
colored as pale brown amorphous powder (60%); mp 
218–219 °C; 1H NMR (500 MHz, DMSO-d6): δ 8.93 (br d, 
J = 7.5 Hz, 1H, H-6), 8.29 (br d, J = 8 Hz, 1H, H-3), 8.26 
(br d, J = 8 Hz, 1H, H-8), 8.23 (br d, J = 7.5 Hz, 1H, H-5), 
7.78 (t, J = 8 Hz, 1H, H-4), 7.67 (t, J = 8 Hz, 1H, H-7), 
3.47 (s, 3H, –SO2–CH3); 13C NMR (125  MHz, DMSO-
d6): δ 165.9 (C-9), 161.3 (>C–S–CH3), 160.4 (C-2), 136.0 
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(C-6), 135.9 (C-3), 131.9 (C-5), 131.7 (C-8a), 128.4 (C-8), 
128.3 (C-4), 127.6 (C-7), 127.4 (C-5a), 117.3 (C-2b), 112.7 
(C-2a), 42.6 (–SO2–CH3); HRMS (EI), m/z Calcd for 
 C14H9N3O3S (M)•+ 299.1296, found 299.1316.
Procedure for preparation of 10‑(phenoxy)‑7H‑benzo[de]
[1,2,4]triazolo[5,1‑a]isoquinolin‑7‑one (4)
A mixture of I or 2 (1 mmol) with diphenoxy-N-cyano-
imidocarbonate (1  mmol) in N,N-dimethyl formamide 
(10  mL) was refluxed in the presence of triethylamine 
for 4–5 h. Afterwards, the mixture was poured into ice/
water, the obtained solid was filtered, washed with water 
and dried. Analytically pure product resulted as brown 
amorphous powder (45%); mp 281–282  °C; 1H NMR 
(500 MHz, DMSO-d6): δ 8.68 (br d, J = 7.5 Hz, 1H, H-6), 
8.45 (br d, J = 8 Hz, 1H, H-3), 8.31 (br d, J = 8 Hz, 1H, 
H-8), 8.01 (br d, J = 7.5 Hz, 1H, H-5), 7.86 (t, J = 8 Hz, 
1H, H-4), 7.78 (t, J =  8  Hz, 1H, H-7), 7.48 (dt, J =  8.5, 
1 Hz, 2H, H-3′/5′), 7.28 (dd, J = 8.5, 1 Hz, 2H, H-2′/6′), 
7.16 (br t, J  =  8  Hz, 1H, H-4′); 13C NMR (125  MHz, 
DMSO-d6): δ 167.1 (C-OPh), 165.8 (C-9), 155.6 (C-2), 
150.5 (C-1′), 136.9 (C-6), 135.1 (C-3), 133.1 (C-5), 
132.7 (C-8a), 129.8 (C-3′/5′), 128.6 (C-8), 128.2 (C-4), 
127.9 (C-7), 126.3 (C-5a), 123.8 (C-4′), 122.5 (C-2b), 
119.2 (C-2′/6′), 118.6 (C-2a); HRMS (EI), m/z Calcd for 
 C19H11N3O2 (M)•+ 313.1296, found 313.1310.
Procedure for preparation of 8‑hydrazinocarbonyl‑1‑ 
naphthoic acid (6)
A solution of 2 (1 mmol) in DMF (10 mL) was refluxed 
with Conc. HCl (15  mL) for 24  h. The mixture poured 
into ice/water, the obtained solid was separated, washed 
with water and dried. Analytically pure product resulted 
as yellow powder (60%); mp 225–226  °C; 1H NMR 
(500 MHz, DMSO-d6): δ 14.30 (s, 1H, –COOH), 8.97 (br 
s, 3H, –NH–NH2), 8.56 (br d, J = 7.5 Hz, 1H, H-2), 8.48 
(br d, J =  7.5  Hz, 1H, H-4), 8.39 (br d, J =  7.5  Hz, 1H, 
H-5), 8.32 (br d, J = 7.5 Hz, 1H, H-7), 7.91 (t, J = 8 Hz, 
1H, H-3), 7.85 (t, J = 8 Hz, 1H, H-6); 13C NMR (125 MHz, 
DMSO-d6): δ 166.4 (–COOH), 158.9 (–CONH–NH2), 
135.7 (C-2), 134.9 (C-4), 132.4 (C-5), 131.9 (C-4a), 131.7 
(C-8), 131.7 (C-7), 127.3 (C-6), 124.6 (C-3), 123.8 (C-8a), 
117.7 (C-1); HRMS (EI), m/z Calcd for  C12H10N2O3 (M)•+ 
230.0691, found 230.0709.
Animals
Adult albino rats weighing 130–150  g were obtained 
from the animal house colony in the National Research 
Centre (Giza, Egypt). Animals were subjected to con-
trolled conditions of temperature (25 ±  3  °C), humidity 
(50–60%) and illumination (12-h light, 12-h dark cycle, 
lights on at 08:00  h) and were provided with standard 
pellet diet and water ad libitum for 1 week before starting 
the experiment.
Anti‑inflammatory activity
The anti-inflammatory effect was evaluated in cor-
respondence to the carrageenan-induced paw edema 
method [22]. Briefly, carrageenan (1% w/v, 0.1 mL/paw) 
was injected into right hind paw at the plantar side. Rats 
were observed for abnormal behavior and physical con-
dition after carrageenan injection. The right paw was 
measured once before (normal baseline) and then after 
carrageenan injection at 1, 2, 3, and 4 h. Twenty groups 
of female Sprague–Dawley rats were used (n = 6, weigh-
ing 130–150  g). According to the procedure reported 
in the literature, the first group represented the control 
carrageenan injected, the second was given indometha-
cin (Sigma, USA) orally, the reference anti-inflammatory 
drug (10  mg/kg) [23], and the remaining groups were 
treated with the tested compounds (25  mg/kg body-
weight) orally, 1  h before carrageenan (Sigma, USA) 
injection. Paw volume was measure by using a water 
displacement plethysmometer (UGO BASILE 21025 
COMERIO, ITALY). The percentage increase in paw 
volume was calculated using (Oedema volume of test/
baseline volume) * 100 − 100. Moreover, percentage (%) 
inhibition was calculated using (1 − D/C) × 100, where, 
D-represents the percentage difference in increased paw 
volume after the administration of test drugs to the rats. 
C-represents the percentage difference of increased vol-
ume in the control groups Fig. 1.
Anti‑arthritic activity
Induction of arthritis and treatment protocol
Adjuvant arthritis (AA) was induced in female Wistar 
rats by subcutaneous (SC) injection of 0.1  mL CFA 
(Sigma-Aldrich, USA) into the plantar surface of the right 
hind paw, which exhibits many similarities to human RA. 
The severity of the induced adjuvant disease was followed 
by measurement of the volume of the injected paw by 
using a water displacement plethysmometer (UGO Basile 
21025, Comerio, Italy). The paw volume of the injected 
right paw over vehicle control is measured at every week 
during experiment [24]. Rats were randomly divided into 
four groups of six rats each: normal control, untreated 
arthritis group, compound 9 treated, and compound 15 
treated arthritis groups. Results were expressed as the 
percentage increase in paw volume.
Thermal sensitivity hotplate test
Rats were placed on the hotplate at 55 °C, one at a time 
(Columbus Instruments, Columbus, OH). The latency 
period for hind limb response (e.g. shaking, jumping, or 
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licking) was recorded as response time. Each trial had a 
maximum time of 45  s. The rat was removed from the 
hotplate immediately after a response was observed [25].
Motor coordination assessment methods for RA
Motor coordination and balance was assessed using a 
rota rod apparatus (Med Associates, Italy) [26, 27]. All 
rats underwent a 3-day training program, by which time a 
steady baseline level of performance was attained. During 
that period, rats were trained to walk against the motion 
of a rotating drum at a constant speed of 12  rpm for a 
maximum of 2  m. In total, four training trials per day 
with an interval trial time of 1  h were performed. Rats 
falling off during a training trial were put back on the 
rotating drum. Following the training days, a 1  day test 
of three trials was performed using an accelerating speed 
levels (4–40 rpm) over 5 min. The apparatus was wiped 
with a 70% ethanol solution and dried before each trial. 
The mean latency to fall off the rotarod was recorded, 
and rats remaining on the drum for more than 300 s were 
removed and their time scored as 300 s.
Radiographic assessment of arthritis in rat paws
Radiographic assessment was used blindly at end of the 
disease to evaluate the severity of OA radiography, using 
an X-ray collimator, model R-19, lamp-type 24 V, 90 W, 
on-load voltage 19  V (Ac max KVP 100 KVP min. inh, 
filt. 1 m, Japan). At the end of the experiment, 24 h after 
the last dose of treatment, blood samples were collected 
under light anaesthesia with diethyl ether by puncturing 
rato-orbital plexus; the blood was allowed to flow into a 
dry, clean centrifuge tube and left to stand 30 m before 
centrifugation to avoid haemolysis. Then, blood samples 
were centrifuged for 15  m at 2500  rpm, and the clear 
supernatant serum was separated and collected by Pas-
teur pipette into a dry, clean tube to use for determina-
tion of the serum levels of PGE2, COX2 and IL-1β [28].
Statistical analysis
Data were expressed as mean  ±  SEM and analysed by 
one-way analysis of variance (ANOVA) for multiple com-
parisons followed by Tukey’s post hoc comparisons. All 
analyses were performed by SPSS statistics package ver-
sion 17.0 (SPSS, Chicago, IL, USA). P value of ≤0.05 was 
considered statistically significant.
Molecular modelling
All compounds were prepared using MOE (Molecular 
Operating Environment, 2011) and CORINA [29, 30]. 
Murine cyclooxygenase-2 (COX-2) enzymes co-crys-
tallized with indomethacin (PDB entry 4COX [31, 39]) 
and co-crystallized with naproxen (PDB entry 3NT1 [32, 
34]) were used as templates for the modeling study. Since 
indomethacin and naproxen have different interactions 
with COX-2, both inhibitors were used as references in 
this study [32].
The software GOLD version 5.2 [33] was used to per-
form docking. The crystal structure depicted under 
PDB entries 4COX and 3NT1 were first protonated, and 
water molecules as well as co-crystallized ligands were 
deleted before docking. In this study, default parameters 
were used with no constraints (binding site: within 10 Å 
around the co-crystallized ligand, scoring functions: 
GOLDScore, genetic algorithm: 100% search efficiency). 
Validation of the docking protocol was performed by 
recovering the original conformation of the co-crys-
tallized inhibitor inside the active site. The root mean 
square deviation (RMSD) between the docked pose and 
the crystal structure of 0.7  Å was measured for indo-
methacin, and 0.25 Å for naproxen (Fig. 5).
The followed strategy in this work was to generate 
ten docking poses for each compound using GOLD, 
and compare them to the one of the two co-crystallized 
inhibitors. This state-of-the-art approach developed 
in our group has been applied and validated in various 
recent studies [34–37]. Using the software LigandScout 
3.1 [35], a 3D pharmacophore model that represents the 
steric interactions of the co-crystallized inhibitor inside 
the COX-2 pocket was created (Fig. 5) and used as a scor-
ing function to analyze the resulting docking poses.
All generated docking poses were minimized with 
the MMFF94 force field inside the COX-2 pocket using 
LigandScout 3.1 [35]. The 3D-pharmacophore of indo-
methacin and the quality of the superposition of each 
pose with the co-crystallized ligand were used to pri-
oritize the poses that could best explain the biological 
behaviors of the studied molecule. Those only were used 
for comparing and discussing inhibitors binding modes. 
LigandScout was also used for analysis, pharmacophore 
creation, and visualization.
Crystal structure determination for compound 5 (CCDC 
1049988)
Yellow needle-shaped crystals of crystal structure 
determination for compound XX of  C14  H9  N3  O3  S1 
are, at 293 (2) K Monoclinic, space group P21/n, with 
a = 13.7295 (10) Å, b = 12.0853 (10) Å, c = 16.2631 (12) Å, β = 114.859 (2)°, V = 2448.4 (3) Å3 and Z = 7 formula 
units  [dcalcd  =  1.624  Mg/m3; µ (MoKα)  =  0.28  mm−1]. 
A full hemisphere of diffracted intensities was meas-
ured using graphite monochromated MoK radiation 
(=0.71073 Å) on a Bruker SMART APEXII D8 Venture 
Single Crystal Diffraction System. X-rays were provided. 
The Bruker software package SHELXTL [36] was used to 
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solve the structure using “direct methods” techniques. All 
stages of weighted full-matrix least-squares refinement 
were conducted using Fo2 data with the SHELXTL soft-
ware package.
The final structural model incorporated anisotropic 
thermal parameters for all non hydrogen atoms and 
isotropic thermal parameters for all hydrogen atoms. 
The remaining hydrogen atoms were included in the 
structural model as fixed atoms (using idealized  sp2- or 
 sp3-hybridized geometry and C–H bond lengths of 0.95–
0.98 Å) “riding” on their respective carbon atoms. The 
isotropic thermal parameters for these hydrogen atoms 
were fixed at a value 1.2 (non-methyl) or 1.5 (methyl) 
times the equivalent isotropic thermal parameter of the 
carbon atom to which they are covalently bonded. A 
total of 369 parameters were refined using no restraints 
and 2 data. Final agreement factors at convergence are: 
 R1 (unweighted, based on F) = 0.096 for 4307 independ-
ent “observed” reflections having 2θ (MoKα)< 50.0° and 
I > 2(I);  wR2(weighted, based on  F2) = 0.264 for all 2979 
independent reflections having 2θ (MoKα)< 50.0°.
Results
Chemistry
As dioxo-benzo[de]isoquinolin-2-yl)thiourea (1) was 
required as key starting material (see Scheme  1), it was 
previously prepared by the reaction of 1,8-naphthalic 
anhydride (A) with thiosemicarbazide. This compound 
was then characterized by X-ray crystallography (Figs. 2, 3) 
[37]. The symmetric structure of the 2-amino-1H-
benzo[de]isoquinolin-1,3-dione moiety in 1 shows simi-
lar NMR splitting patterns and δ-values (δH and δC) to 
A, including three pairs of two equivalent aromatic pro-
tons (H-3/8, H-5/6 and H-4/7) and their corresponding 
13C-signals. Presence of the thio-urea moiety was sup-
ported by the –NH and –NH2 singlets at δH 9.82 and 7.99, 
respectively alongside C=S carbon at 181.8 in 1H and 13C 
NMR spectra. Finally, HREI-MS confirmed the identity 
of 1 through a molecular ion peak (M)•+ at m/z 271.1013 
calculated for 271.0983 and a MF of  C13H9N3O2S. Reac-
tion of 1 with hydrazine hydrate in presence of NaOH 
produced product 2 in good yields (78%). Structure of 
2 was confirmed by 13C-NMR analysis, which showed 
Scheme 1 Synthetic routes for products 1‒20. a Thiosemicarbazide, glacial acetic acid, reflux; b dimethyl‑N‑cyanoimido(dithio)carbonate, diphe‑
noxy‑N‑cyanoimi ‑docarbonate, Et3N, DMF, H2O2, galcial acetic acid, reflux; c NaOH, NH2NH2, HCl, DMF, refux; d aldehydes, isothiocyanates, acetic 
anhydrides, DMF, glacial acetic acid, reflux; e HCl, DMF, reflux; f dimethyl‑N‑cyanoimido(dithio)carbonate, diphenoxy‑N‑cyanoimidocarbonate, Et3N, 
DMF, H2O2, galcial acetic acid, reflux; g dimethyl‑N‑cyanoimido(dithio)carbonate, diphenoxy‑N‑cyanoimidocarbonate, Et3N, DMF, reflux
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the disappearance of C=S at 181.80  ppm. Based on the 
high reactivity of 1 towards hydrazine, it was anticipated 
that 1 would react with N-cyanoimido(dithio)carbon-
ates in a similar manner in presence of  Et3N to give novel 
benzo[de][1,2,4]triazolo[5,1-a]isoquinolines 3 and 4. Fur-
ther oxidation of methylthio in 3 using  H2O2 yielded in 
the novel benzo[de][1,2,4]triazolo[5,1-a]isoquinoline 5. 
Similarly, treatment of 2 or 6 with N-cyanoimido(dithio)
carbonates with basic medium, resulted in compounds 3 
and 4, respectively (Scheme 1).
Ring-closure of products 3–5 was reflected into the 
deformation of the symmetrical structures of the 2-ami-
noisoquinoline moiety, which appeared in the 1H NMR 
spectra as four broad doublets (H-3, 5, 6 and 8) and two 
triplicates (H-4, 7) signals. Also, ring-closure of a fused 
triazole ring was confirmed from the characteristic δ 
values of C-2 (≈156–160  ppm), carbonyl-carbon (C-9) 
at about δ 166 ppm and the methythio-, methylsulfonyl- 
and phenoxyl-bearing carbon signals at 156.6, 161.3 and 
167.1, respectively. 1H NMR of 3 and 5 showed a char-
acteristic singlet of methylthio and methylsulfonyl at 
δ 2.73 and 3.74 together with their carbons at 14.2 and 
42.6  ppm, respectively, to prove the insertion of such 
functional groups. The phenoxyl group in the struc-
ture of 4 was concluded through its characteristic reso-
nances at 7.48 (dt, J = 8.5), 7.28 (dd, J = 8.5) and 7.16 (br 
t, J = 8), attributable for H-3′/5′, H-2′/6′, and H-4′, and 
their C-signals at δ 129.8, 119.2, and 123.8, respectively. 
The success of the previous reactions was finally proven 
by the unambiguous confirmation of the 3D-structure 
of methylsulfonyl product 5 by X-ray crystallography 
(Figs. 2, 3). The open structure 6 was obtained by heat-
ing compound 2 with concentrated HCl in DMF for 24 h 
under reflux (Scheme 1). This structure was confirmed by 
the two singlets at δ 14.30 and 8.97 ppm, interpretable for 
–COOH and –NH–NH2 protons, together with the cor-
responding carbonyl 13C-resonances at δ 166.4 and 158.9, 
for –COOH and –CONHNH2, respectively. Compounds 
7–20 were synthesized from 2-amino-1H-benzo[de]
Fig. 1 Reduction of rat’s paw edema induced by carrageenan after administration of tested compounds
Fig. 2 ORTEP diagram of compound 1
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isoquinolin-1,3-dione (2) (Table  1) and reported in our 
previous work [38].  
Anti‑inflammatory activity
In-vivo anti-inflammatory effects of the synthesized 
benzo[de]isoquinolines 1–20 were then evaluated using 
standard carrageenan-induced paw edema in rats, indo-
methacin as reference drug. Paw swelling is good index 
for evaluating and assessing the degree of inflamma-
tion and the therapeutic and curative effects of bioactive 
compounds. The response of target compounds 1–20 
ranged from weak to moderate activity, however, some of 
compounds exhibited promising effects in a direct cor-
relation with their structural variation. In comparison 
to the control and reference drugs, all investigated com-
pounds show significant reduction of paw size through-
out a 4 h time period (Additional file 1: Table S1; Fig. 1).
Anti‑arthritic activity
In chronic inflammation, CFA-induced arthritic model 
is considered the best known experimental model of 
rheumatoid arthritis (RA) and a model of chronic polyar-
thritis with features that resemble RA. Basis on the prom-
ising anti-inflammatory activity results of compounds 9 
and 15, we extended our research to evaluate their anti-
arthritic effects in doses of 50 mg/kg administered orally. 
For monitoring the progression of arthritis in a CFA-
induced albino rat model, a number of assessment meth-
ods as thermal sensitivity hotplate, motor coordination 
and radiographic were applied. The changes in the body 
weight of the CFA-induced arthritis in rat with com-
pounds was measured (Fig.  4a). Measurement of paws 
was performed by using a plethysmometer (Fig. 4b). The 
sensitivity and reaction to pain stimulus was indicated 
by hotplate (Fig.  4c). The serum level of Interleukin-1β 
(IL-1β, cyclooxygenase-2 (COX2) and prostaglandin E2 
(PGE2) of the CFA treated rat were measured and com-
pared to the control group (Table 2). Soft tissue with nor-
mal bone density of the rat’s hind paws was examined by 
X-ray (Additional file 1: Figure S1A).
Fig. 3 ORTEP diagram of compound 5
Table 1 Synthesized compounds 1‒20
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Molecular modelling
With the aim to predict the most plausible binding 
mode of the identified inhibitors in this work and to 
rationalize their structure–activity relationship (SAR), 
molecular docking was performed in the COX-2 active 
site. To investigate the inhibition of these synthe-
sized compounds, ten docking conformations were 
generated, carefully analyzed and prioritized using 
a 3D-pharmacophore representation of the binding 
modes of the reference inhibitors, indomethacin and 
naproxen. Since the sequence of murine COX-2 active 
site is 87% identical to the one in human, PDB entry 
4COX of murine COX-2 co-crystallized with indo-
methacin, and PDB entry 3NT1 co-crystallized with 
naproxen were selected for this computer-aided study 
[39]. The docking program GOLD 5.2 [33] was used to 
reproduce the binding mode of the co-crystallized indo-
methacin in the ligand–protein complex 4COX [39] and 
the co-crystallized naproxen inside the complex 3NT1 
[32]. The root mean square deviation (RMSD) between 
the heavy atoms of the original co-crystallized ligand, 
and the docked conformation ligand was calculated in 
GOLD 5.2. Validation of docking experiments for the 
PDB codes 4COX and 3NT1 for COX-2 enzyme are 
depicted in Additional file  1: Figure S2. The co-crystal 
of indomethacin in the COX-2 active site (PDB entry 
4COX) and naproxen inside the COX-2 active site (PDB 
entry 3NT1) were analyzed (Fig. 5a, b).
Docking results were evaluated by MolDock score 
function and hydrogen bond and hydrophobic interac-
tions between tested compounds and the target receptor 
were used to compare between the tested compounds 
and the reference compounds (Table 3).
Docking with indomethacin as reference inhibitor
Firstly, software LigandScout [35] was used to analyze 
molecular interactions of indomethacin and naproxen 
Fig. 4 a Changes in body weight of CFA‑induced RA in rat with compounds 9 and 15. b Effect of test compounds (50 mg/kg) on CFA‑induced 
arthritis in rats with compounds 9 and 15. c Effect on hotplate time response with compounds 9 and 15. d Effect on spontaneous motor activity 
in CFA rats with compounds 9 and 15. Data represent the mean ± SEM (n = 6 for each group); *significance versus control (P ≤ 0.05); asignificance 
versus CFA group (P ≤ 0.05)
Table 2 Effect of  test compounds 50  mg/kg on  serum 
IL-1β, COX2 and PGE2 of rat CFA
Data represent the mean ± SEM (n = 6 for each group)
a Significance versus control (P ≤ 0.05)
b Significance versus CFA group (P ≤ 0.05)
IL‑1β (pg/mL) COX2 (ng/mL) PGE2 (pg/mL)
Control (vehicle) 26.8 ± 1.4 15.9 ± 0.4 17.3 ± 0.9
CFA 93 ± 2.2a 46.3 ± 1.5a 65.9 ± 2.3a
Compound 9 37.4 ± 1.1a,b 16.9 ± 0.7b 22.6 ± 0.7b
Compound 15 41.9 ± 0.9a,b 20.8 ± 0.5a,b 25.4 ± 0.3a,b
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in the COX-2 active site. Three kinds of interactions can 
be identified for indomethacin inside COX-2 active site: 
hydrophobic contacts between aromatic rings of indo-
methacin and hydrophobic residues Phe381, Leu384, 
Met522, Tyr385, Trp387, Leu531, Leu352, Ala527 and 
Val523 in the active site, a salt bridge formed between 
Arg120 and the carboxylate group of the inhibitor, and 
hydrogen bonds between the inhibitor and Tyr355, 
Arg120, and Ser530. The original conformation of indo-
methacin in the crystal structure  4COX was used as a 
reference for investigating and prioritizing the generated 
docking poses. The resulting conformations of the stud-
ied compounds were analyzed and the most plausible 
poses were selected based on their ability to create simi-
lar interactions as the one of the reference inhibitor.
Fig. 5 a Binding mode of indomethacin co‑crystallized with COX‑2 as 3D (left) and 2D (right), PDB entry 4COX. b Binding mode of naproxen co‑
crystallized inside COX‑2 active site as 3D (left) and 2D (right), PDB entry 3NT1. Pharmacophore features created using LigandScout. Red arrows: 
H‑bonds, red star: negative ionizable feature, yellow spheres: hydrophobic contacts
Table 3 MolDock scores of tested compounds
Ligand MolDock score Ligand MolDock score
1 −99.3452 11 −114.071
2 −98.9549 12 −109.498
3 −107.022 13 −111.854
4 −121.189 14 −103.154
5 −68.9738 15 −128.385
6 −92.9481 16 −94.8682
7 −108.334 17 −98.9912
8 −110.781 18 −128.489
9 −106.802 19 −104.212
10 −120.592 20 −71.3571
Indomethacin −151.314
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Docking of compound 15 reveals an ability to partially 
accommodate the same region as the reference inhibitor 
inside the pocket (Fig. 6). Compound 15 shows binding 
through hydrophobic contacts formed between its fused 
aromatic rings and Val523 and Val349, as observed for 
indomethacin. Additional hydrophobic contacts can be 
formed between the fused aromatic rings and Ala527, 
Leu531, Leu352, and Phe518. One hydrogen bond can be 
formed between the carbonyl oxygen of 15 and Tyr355. 
Superposition of 15 with indomethacin shows how both 
ligands can occupy the same region in the pocket, which 
can explain why 15 is the most potent inhibitor in this 
series (Fig. 6).
Docking with naproxen as reference inhibitor
Naproxen is another reference inhibitor that is stabi-
lized in the active site of COX-2 with a different bind-
ing mode compared to indomethacin. It is important to 
investigate the ability of our compounds to interact with 
COX-2 using a binding mode more similar to the one of 
naproxen as the one of indomethacin. Therefore, the gen-
erated binding conformations of our inhibitor series was 
aligned to a 3D-pharmacophore model extracted from 
the COX-2-naproxen co-crystal (PDB entry 3NT1) [32]. 
The ability of these molecules to fulfill similar interac-
tions as the one identified in this crystal structure was 
analyzed using LigandScout.
The plausible binding mode of 9, the most potent 
inhibitor in this series, shows interesting interactions 
with the binding site of COX-2. Besides the stabilization 
of ligands inside the pocket with hydrophobic contacts, 
hydrogen bonds can be formed between the methoxy of 
compound 9 (up to 72%) and Arg120, and a carbonyl of 9 
with Ser530 (Fig. 7). This interaction may serve to anchor 
the compound within the active site similar to naproxen 
and enforce the binding orientation.
Discussion
The results revealed that many of the tested compounds 
caused significant decrease in paw edema after 1, 2, 3, 
4 h from drug administration. The edema inhibition per-
centages measurements show that after 1  h compounds 
2, 3, 12, 14 and 18 were inactive. The same result was 
observed after 4  h with compound 20. Compounds 4, 
10, 11, 13, and 19 showed low activity (0.63, 9.60, 11.75, 
10.12 and 10.36% of inhibition, respectively) 1  h after 
drug administration, while 12 and 18 showed 14.89 and 
17.60% of inhibition after 2 h. 1 h after drug administra-
tion, compounds 5–7, 9, 16, 17 and 20 were found to 
possess a good biological response (from 20.61 to 31.45%) 
compared to indomethacin (18.98%), and compound 15 
emerged as the most potent (66.13%), 3.5 more than ref-
erence indomethacin (Additional file  1: Table S1). With 
respect to the effect of indomethacin after 2 h, a similar 
tendency were observed for compounds 8 and 15; 1, 5–8, 
11, 13, 16, 17 and 20 showed a comparable good activity; 
a moderate effect was observed by 2–4, 10, 14 and 19, 
however, compound 9 showed a stronger effect (72.72%) 
than indomethacin (61.22%). Similarly, after 3  h, com-
pounds 6, 8, 9 and 14–17 showed good activity (56.55–
71.09%); and moderate inhibition was observed for 
compounds 1–5, 7, 10–13, 19 and 20 (31.72–48.09%), 
while indomethacin inhibited 80.15% of the induced 
edema. 4 h after drug administration, compounds 1, 6, 8, 
Fig. 6 The predicted binding mode of 15 in the COX‑2 pocket (PDB: 4COX). Above: 3D (left) and 2D (right). Yellow spheres denote hydrophobic 
contacts. Red arrow represents hydrogen bond acceptor
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9, and 13–18 exhibited remarkable and significant activ-
ity (51.67–67.20%) compared to indomethacin (85.70%); 
a moderate effect was observed for compounds 3–5, 7 
and 11 (32.81–46.66%), and compounds 2, 10, 12 and 19 
showed the lowest potency (Fig. 1).
Transformation of 1 into 2–4 attenuated the anti-
inflammatory effect. However, subsequently transfor-
mation of 2 and 3 into 6 and 5 respectively, was offered 
advantageous influencing in the terms of activity. Open-
ing the bulky-sized structure 2 into 6 is crucial for induc-
ing the anti-inflammatory effects. Various effects were 
recorded upon chemical transformation of 2 into 7–20, 
particularly compounds 8, 9 and 14 that appeared to be 
the most active products among aldehyde derivatives 7–
14. This could be attributed to the presence of hydroxyl 
group on benzyl ring in the structure of 8, and methoxy 
group in 9 which they could be displayed an essential role 
in activity. However, the presence of a hetero atom in 14 
does seem to offer remarkable advantage for activity. This 
indicates that increasing the number of hetero atoms that 
can act as hydrogen bond donor could be responsible for 
the improvement of anti-inflammatory activity. Incorpo-
ration of a crucial structural feature of cyclohexyl isothio-
cyanate in 2 to afford 15 increased the anti-inflammatory 
activity. Furthermore, an improvement in the activity was 
observed by insertion of succinic anhydride function in 
the structure of 2 to give 16.
In regards to chronic inflammation, compound 9 and 
15 have demonstrated a significant effect on the CFA-
induced arthritic model. When compounds 9 and 15 
were administered daily for 3  weeks (starting from 
day 7 of the CFA induction); non-significant change in 
body weight was noticed, however a significantly reduc-
tion (52%) on the body weight of the CFA-induced RA 
group was observed in comparison to the control group 
(Fig.  4a). As illustrated in Fig.  4b, an adjuvant injection 
resulted in an acute inflammatory phase of swelling in 
the injected paws for 3  days and an autoimmune phase 
of swelling in both injected and non-injected paws after 
10 days. Compounds 9 and 15 markedly reduced the vol-
umes of injected paws in comparison to the CFA (RA) 
group.
The sensitivity and reaction to pain stimulus was indi-
cated by hotplate, to which the response of the CFA 
group rats was slower than the control group. Treatment 
of the CFA rats with compounds 9 and 15 normalized the 
response compared to the control group (Fig. 4c), signifi-
cantly altered the total number of movements (P ≤ 0.05) 
in the locomotor activity at the end of the experiment 
(Fig. 4d), and reduced the serum level of Interleukin-1β 
(IL-1β, cyclooxygenase-2 (COX2) and prostaglandin E2 
(PGE2) compared to the control group (Table 2).
Examination of the rats hind paws by X-ray showed 
normal soft tissue with normal bone density (Additional 
file  1: Figure S1A). Aggravated swelling with bone ero-
sion in the articular facet and joint space that was prac-
tically devastated was observed after 28  days from CFA 
induction (Additional file 1: Figure S1B). Treatment with 
compounds 9 and 15 showed increasing swelling of soft 
paw tissue with a diminution in bone density (Additional 
file 1: Figure S1C) and some minimal soft tissue swelling 
(Additional file 1: Figure S1D) respectively.
Kinetic, mutagenesis, structure–activity relationship 
analysis and x-ray crystallography studies of naproxen 
and indomethacin elucidated the molecular determi-
nants for COX inhibition [32]. Because a detailed com-
parison of the binding mode of these two drugs could 
unveil the responsible features for selectivity, analysis of 
Fig. 7 Left: predicted binding modes of 2 (blue sticks), and 3 (green balls and sticks) superimposed with original conformation of naproxen (black 
lines) inside the COX‑2 active site (PDB entry: 3NT1). Red arrows represent hydrogen bonds. Right: suggested binding modes for 9 (green sticks) 
superposed with the original conformation of naproxen (black lines) inside the COX‑2 active site (PDB entry: 3NT1)
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the enzyme-inhibitor interaction for indomethacin and 
naproxen co-crystallized with COX-2 was conducted 
using a pharmacophore approach with software Ligand-
Scout [35]. Compounds 1–20 have MolDock scores 
range from −68.9 to −128.4. Compounds 18 and 15 
which have highest MolDock score in this experiment 
128.4 and 128.3, respectively. Compound 15 which has 
the best percentage of edema inhibition in this study 
give also best MolDock score (Table  3). The co-crystal 
of indomethacin in the COX-2 active site (PDB entry 
4COX) shows three critical interactions: (i) hydropho-
bic contacts between aromatic rings of indomethacin 
and hydrophobic residues Phe381, Leu384, Met522, 
Tyr385, Trp387, Leu531, Leu352, Ala527 and Val523 in 
the active site (ii) a salt bridge formed between Arg120 
and the carboxylate group of the inhibitor, and (iii) 
hydrogen bonds between the inhibitor and Tyr355, 
Arg120, and Ser530 (Fig.  5a). Analysis of naproxen 
inside the COX-2 active site (PDB entry 3NT1) indi-
cates a binding mode similar from the one of indometh-
acin. The key interactions with Arg120 and Tyr355 with 
the carboxylate group of the ligand interactions are con-
served, and most hydrophobic contacts observed in the 
main pocket are accommodating the lipophilic moieties 
of the inhibitor. The only difference between the two 
inhibitors is the chlorobenzoyl group of indomethacin 
that reaches another region of the active site (Tyr385, 
Leu384, Phe381) that naproxen cannot reach because of 
its smaller size (Fig. 5b).
The investigation of docking conformations for the 
most potent inhibitors in this series indicates the impor-
tant role of hydrophobic contacts to stabilize ligands 
inside the pocket. However, the lack of interaction with 
the critical Tyr385 with most of these series implies their 
moderate/weak potencies against COX-2. Interestingly, 
Compound 15 shows fast inhibitory potency (66%) from 
the first hour and remains relatively stable even after 4 h 
(58%). Thus, it is worth to investigate this series using 
a reference such as naproxen that has different binding 
mode compared to indomethacin. The binding confor-
mation of compounds 15 and 9 forming hydrogen bonds 
with Tyr355 in similar manner to naproxen confirms 
the importance of Tyr355 and confirms the findings 
highlighted with indomethacin. Also, the unique forma-
tion of hydrogen bond between Arg120 and naproxen 
can be observed with compounds 9 and 15. This result 
suggests that the most potent inhibitor in this series, 
compound 15, has a binding mode that is highly corre-
lated with the conformation of naproxen inside COX-2 
active site. Moreover, compound 9 can interact through 
Leu352, Val349, Ser530, Trp387, Tyr385 and its carbonyl 
group with Tyr355 by hydrogen bonding. These inter-
actions can explain that compound 9 is higher potency 
than compound 15 (up to 66%), which lacks these 
interactions.
By using a combined approach of biological activ-
ity and molecular modeling, we were able to probe the 
importance of 9 and 15-COX-2 interactions and eluci-
date key interactions and compare it with indometha-
cin and naproxen. The combination of mutagenesis and 
structural studies will clearly define the contribution of 
protein and inhibitor atoms to affinity with compound 9 
and 15, which will be applied in the future.
Conclusion
The present investigation explored the significance of 
the molecular-hybridization development of novel com-
pounds with strong activity against the inflammation-
induced-by-carrageenan model. Compounds 8, 9, 15 and 
16 were the most potent compounds of the series, which 
can be explained by a similar binding mode to references 
indomethacin and naproxen. Moreover, the results pre-
sented here support the notion that compound 9 and 15 
are active against rheumatoid arthritis and significantly 
reduce the serum level of Interleukin-1β [IL-1β], cyclooxy-
genase-2 [COX2] and prostaglandin E2 [PGE2] in the CFA 
rats. The investigation of the inhibitor in the COX-2 bind-
ing site by molecular modeling confirms the importance 
of the hydrogen bonds formation with Tyr355 and Arg120 
and its role in the potency of the newly synthesized inhibi-
tors. Furthermore, the hydrophobic contacts formed by 
compounds 9 and 15 with Tyr385 suggest binding modes 
that are highly correlated with the conformation of nap-
roxen and indomethacin inside COX-2 active site. These 
compounds offer a base for further investigation of a novel 
anti-inflammatory and anti-arthritic agents.
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